Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for Slow Coronary Flow in STEMI
NCT07195812Phase 4Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Oct 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of rivaroxaban in ST-segment elevation myocardial infarction (STEMI), no-reflow phenomenon, sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
ST-segment elevation myocardial infarction (STEMI)no-reflow phenomenon
Beyond the preview
Go deeper on NCT07195812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07195812.